Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Mol Cancer Res. 2021 May 26;19(9):1510–1521. doi: 10.1158/1541-7786.MCR-21-0053

Fig. 3. Association between HLA-I evolutionary divergence (HED) and outcomes.

Fig. 3.

(a) Clinical outcomes of the cohort in relation to the mean HED values calculated for each patient. Each column represents an individual. The outcomes are represented by the top bars which are colored by the mean HED value. The bottom tiles represent relevant prognostic factors for RCC that were used for adjustment in multivariable analysis. (b) Kaplan-Meier curves showing the relationship between HLA diversity and clinical outcomes. Zygosity at HLA-class I loci was not significantly associated with progression-free survival (PFS), while high mean HED was found to be predictive of longer progression-free survival, as well as longer durability of response (DOR). (c) Forest plots showing results from the multivariable Cox regression analysis. Mean HED was found to be significantly associated with improved PFS and DOR even after adjusting for known prognostic factors.